DarioHealth Receives “First Choice” Recognition in the UK
Market leader DarioHealth continues UK success by being named the “First Choice” by the CCGs for all type 1 diabetics in three regions
Jul 10, 2017
CAESAREA, Israel, July 10, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that the CCGs (Clinical Commissioning Groups) in three UK regions have named the Dario™ Blood Glucose Monitoring System the first choice for all patients with type 1 diabetes, in the area of “Smart meters with Carb counting.”
This is an important breakthrough for DarioHealth, as the CCGs are clinically-led statutory NHS bodies responsible for the planning and commissioning of health care services for their local area. The three regions that now officially recognize Dario as the “first choice” option are Darlington; North Durham; and Durham Dales, Sedgefield, and Easington CCGs.
Erez Raphael, Chairman and CEO of DarioHealth, commented, “This is a big milestone for DarioHealth and our UK distributor, Advanced Therapeutics (UK) Ltd. The Dario all-in-one diabetes management system can help users form good habits, keeping them out of hospitals. This assists in lowering the burden for services from both a financial and healthcare standpoint. We believe our being named as “First Choice” by CCGs for all type 1 diabetics in the relevant regions will help us gain more market share in the UK, as more and more healthcare professionals will look to DarioHealth’s solutions for their patients.”
Dr. Kenneth Robertson, a Consultant Paediatrician leading the Greater Glasgow and Clyde Children’s Diabetes Service, the largest children’s service in the UK, who has worked with patients using Dario, is equally impressed, and commented, “In an increasingly crowded and competitive marketplace for capillary blood glucose testing, the Dario system offers a distinct and attractive product.
“Users are rarely impressed with ISO compliance but rather by looks and utility. The Dario scores across the board. The compact and colourful device appeals especially to teenagers and the space-saving compact design results in something easy to carry in a pocket. The real beauty, though, is that the little concealed dongle, when plugged into a smartphone – which no teenager EVER forgets – becomes a more than averagely competent meter, logbook, carbohydrate counting assistant and more besides.
“Parents love the GPS-tagged hypo alerts – great for that party or music festival and the instant Cloud upload aids family and professional support. This is an innovative and well thought through device.”
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, when the Company states its belief that being named as “First Choice” by CCGs for all type 1 diabetics in the relevant regions will help it gain more market share in the UK, as more and more healthcare professionals will look to DarioHealth’s solutions for their patients, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
DarioHealth Investor Relations Contact
Rob Fink / Brett Maas
+1-646-415-8972 / +1-646-536-7331
SOURCE DarioHealth Corp.